A deep learning pathomics platform accurately predicts immunotherapy response in metastatic NSCLC using routine pathology slides.
Key Details
- 1The Path-IO model uses AI to analyze digital pathology slides from NSCLC patients.
- 2Tested on 797 patients (MD Anderson) and validated on 280 international patients (including Lung-MAP S1400I trial).
- 3The model stratified patients into high- and low-risk groups, doubling risk in the high-risk cohort.
- 4Path-IO outperformed PD-L1 biomarker: Path-IO C-indices up to 0.69 (OS) and 0.65 (PFS); PD-L1 indices as low as 0.50-0.58.
- 5Integrating radiomics and clinical data improved prediction performance further (C-index for OS to 0.75, PFS to 0.70).
- 6Study validated across real-world and phase III trial cohorts, though retrospective; prospective validation is the next step.
Why It Matters
This work demonstrates that advanced AI analysis of digital pathology can outperform traditional biomarkers in predicting immunotherapy outcomes. If validated further, such tools could help personalize treatment for cancer patients, offering a significant advance in precision oncology and imaging AI.
Source
EurekAlert
Related News
•EurekAlert
AI Pathology Model Outperforms PD-L1 in Predicting NSCLC Immunotherapy Response
MD Anderson's Path-IO machine learning platform accurately predicts immunotherapy responses in metastatic non-small cell lung cancer, surpassing current biomarker standards.
•EurekAlert
New AI Method Removes Artifacts in Super-Resolution Fluorescence Microscopy
Researchers unveil Adaptive-SN2N, a self-supervised deep learning framework that suppresses background artifacts in super-resolution fluorescence microscopy images.
•EurekAlert
Micro-CT and AI Reveal Hidden Damage in Coral Skeletons
Researchers combined micro-CT imaging and deep learning to detect subtle disease-induced changes in coral skeletons with high accuracy.